Lilly wins oral GLP‑1 approval

Eli Lilly won United States approval on April 1 for Foundayo, a once-daily obesity pill that can be taken without food or water restrictions. (fda.gov) Foundayo is the brand name for orforglipron, a glucagon-like peptide-1 drug that mimics a gut hormone tied to appetite and blood sugar. The Food and Drug Administration cleared it for adults with obesity, or adults with overweight plus at least one weight-related condition, alongside diet and exercise. (fda.gov) (foundayo.lilly.com) The label says patients start at 0.8 milligrams once a day, then step up after at least 30 days at each dose level to as high as 17.2 milligrams. The prescribing information also carries the class warning about thyroid C-cell tumors and says the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (accessdata.fda.gov) Lilly paired the pill launch with a new format for its injectable obesity drug Zepbound: a single-patient-use KwikPen that holds four fixed weekly doses. Lilly says the multi-dose pen is now available in all strengths through LillyDirect’s self-pay pharmacy channel. (pi.lilly.com) (medical.lilly.com) Zepbound was already sold in single-dose pens and single-dose vials, so the KwikPen adds another way to package the same tirzepatide medicine. Lilly’s dosing page lists the single-dose pen, single-dose vial, and KwikPen side by side, with one KwikPen covering a 28-day month. (zepbound.lilly.com 1) (zepbound.lilly.com 2) The two moves come as drugmakers try to widen access to obesity treatment beyond a single device or dosing routine. A pill can appeal to patients who do not want injections, while a four-dose pen can reduce the number of separate injector units needed for a month of therapy. (nature.com) (pi.lilly.com) Lilly’s approval pitch leaned heavily on convenience. In the Phase 3 ATTAIN-1 trial, the company said people on the highest orforglipron dose lost an average of 27.3 pounds, or 12.4 percent of body weight, at 72 weeks under the trial’s efficacy analysis. (prnewswire.com) The Food and Drug Administration said the Foundayo decision was also unusual for another reason: it arrived 50 days after filing and 294 days before the original January 20, 2027 target date under the agency’s National Priority Voucher pilot. The agency called it the fastest approval of a new molecular entity since 2002. (fda.gov) Lilly is pricing the formats differently. The company says Foundayo will be available through LillyDirect starting at $25 a month for commercially insured patients and $149 for self-pay, while Zepbound KwikPen starts at $299 a month for eligible patients whose insurance does not cover the drug. (prnewswire.com) (zepbound.lilly.com) For Lilly, the opening shot is not one new obesity drug but two delivery options at once: a daily pill for people who want to avoid needles, and a monthly pen for people staying on injections. (foundayo.lilly.com) (zepbound.lilly.com)